- Home
- XENE vs KNSA Comparison
XENE vs KNSA Comparison
Compare XENE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | KNSA |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.9B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | XENE | KNSA |
|---|---|---|
| Price | $59.75 | $77.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $68.55 | $60.86 |
| AVG Volume (30 Days) | ★ 621.9K | 384.4K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | $311,000.00 | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $2,496.48 | $17.87 |
| P/E Ratio | ★ N/A | $297.72 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $35.60 | $35.29 |
| 52 Week High | $72.66 | $82.94 |
Technical Indicators
Market Signals| Indicator | XENE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 61.93 |
| Support Level | $52.40 | $44.95 |
| Resistance Level | $62.91 | $82.25 |
| Average True Range (ATR) | 2.20 | 2.17 |
| MACD | -0.22 | -0.50 |
| Stochastic Oscillator | 17.95 | 75.97 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.